Retatrutide handles the heavy lifting on appetite and metabolism, while AOD-9604 fills a gap that no incretin-based peptide can address: direct, receptor-level stimulation of fat breakdown
That profile could be attractive for patients who cannot tolerate benzodiazepines or Z-drugs, though published clinical trial data remains limited
A clear solution is not a guarantee, so respect the storage window and discard a vial once it's past it
According to ProHealth's published quality disclosures, each batch of BPC-157 products undergoes independent third-party testing three times - covering identity, purity, and potency, as well as contaminants including heavy metals, microbial pathogens, residual solvents, and LPS (lipopolysaccharide) contamination